PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:

• Guggenheim's Inaugural Healthcare Innovation Conference (Boston, MA)
  • Monday, November 11, 2024 at 1:00 p.m. ET, Fireside Chat
• Stifel 2024 Healthcare Conference (New York, NY)
  • Tuesday, November 19, 2024 at 11:30 a.m. ET, Fireside Chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the PepGen website at https://investors.pepgen.com/. Replays of the webcasts will be available on the PepGen website for 90 days following the presentation dates.

About PepGen

PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104983620/en/